COSMO Pharmaceuticals SA Market Cap ($1.13 Billion)
Market Cap & Net Worth: COSMO Pharmaceuticals SA (0RGI)
COSMO Pharmaceuticals SA market cap. COSMO Pharmaceuticals SA (LSE:0RGI) has a market capitalization of $1.13 Billion (£844.62 Million) as of October 31, 2026. Listed on the LSE stock exchange, this UK-based company holds position #8062 globally and #29 in its home market, demonstrating a 7.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COSMO Pharmaceuticals SA's stock price £56.30 by its total outstanding shares 15002100 (15.00 Million).
COSMO Pharmaceuticals SA Market Cap History (2015–2026)
COSMO Pharmaceuticals SA market cap history from 2015 to 2026. Data shows change from $3.25 Billion to $1.13 Billion (-9.23% CAGR). Check 0RGI stock price and chart for real-time trading data and today's change.
COSMO Pharmaceuticals SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COSMO Pharmaceuticals SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 0RGI cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
20.21x
COSMO Pharmaceuticals SA's market cap is 20.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.28 Billion | $68.39 Million | $19.34 Million | 48.01x | 169.77x |
| 2017 | $2.91 Billion | $67.71 Million | -$32.45 Million | 42.91x | N/A |
| 2018 | $1.77 Billion | $65.62 Million | -$18.01 Million | 27.00x | N/A |
| 2019 | $1.54 Billion | $62.49 Million | -$24.42 Million | 24.71x | N/A |
| 2020 | $1.71 Billion | $60.95 Million | -$7.90 Million | 27.98x | N/A |
| 2021 | $1.32 Billion | $65.07 Million | $21.67 Million | 20.25x | 60.80x |
| 2022 | $1.24 Billion | $102.09 Million | $17.23 Million | 12.17x | 72.10x |
| 2023 | $1.03 Billion | $92.78 Million | -$4.93 Million | 11.14x | N/A |
| 2024 | $1.28 Billion | $266.79 Million | $133.24 Million | 4.81x | 9.63x |
| 2025 | $2.12 Billion | $104.85 Million | -$3.63 Million | 20.21x | N/A |
Competitor Companies of 0RGI by Market Capitalization
Companies near COSMO Pharmaceuticals SA in the global market cap rankings as of October 31, 2026. See COSMO Pharmaceuticals SA (0RGI) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to COSMO Pharmaceuticals SA by market ranking:
- Pabrik Kertas Tjiwi Kimia Tbk (JK:TKIM): Ranked #8053 globally with a market cap of $1.14 Billion USD ( Rp19.38 Trillion IDR).
- Yunnan Hongxiang Yixintang (SHE:002727): Ranked #8054 globally with a market cap of $1.14 Billion USD ( CN¥7.76 Billion CNY).
- Hubei Biocause Pharmaceutical (SHE:000627): Ranked #8063 globally with a market cap of $1.13 Billion USD ( CN¥7.75 Billion CNY).
- Goosehead Insurance Inc (NASDAQ:GSHD): Ranked #8064 globally with a market cap of $1.13 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8053 | Pabrik Kertas Tjiwi Kimia Tbk | JK:TKIM | $1.14 Billion | Rp6225.00 |
| #8054 | Yunnan Hongxiang Yixintang | SHE:002727 | $1.14 Billion | CN¥13.25 |
| #8063 | Hubei Biocause Pharmaceutical | SHE:000627 | $1.13 Billion | CN¥1.58 |
| #8064 | Goosehead Insurance Inc | NASDAQ:GSHD | $1.13 Billion | $47.61 |
Market Capitalization of COSMO Pharmaceuticals SA (2015–2026)
Market capitalization of COSMO Pharmaceuticals SA from 2015 to today. Between 2015 and today, COSMO Pharmaceuticals SA's market cap moved from $3.25 Billion to $ 1.13 Billion, with a yearly change of -9.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £1.13 Billion | -46.48% |
| 2025 | £2.12 Billion | +65.25% |
| 2024 | £1.28 Billion | +24.13% |
| 2023 | £1.03 Billion | -16.81% |
| 2022 | £1.24 Billion | -5.74% |
| 2021 | £1.32 Billion | -22.73% |
| 2020 | £1.71 Billion | +10.43% |
| 2019 | £1.54 Billion | -12.85% |
| 2018 | £1.77 Billion | -39.01% |
| 2017 | £2.91 Billion | -11.51% |
| 2016 | £3.28 Billion | +1.01% |
| 2015 | £3.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of COSMO Pharmaceuticals SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more